AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37711743 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint intervention between general practitioners and community pharmacists, including training in motivational interviewing and 3 patient interviews after physician inclusion.
Number of subjects: 0
Study 37711905 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 926
Study 37711905 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 926
Study 37712113 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily stimulant use (methamphetamine, amphetamines or cocaine)
Number of subjects: 528
Study 37712113 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily stimulant use
Number of subjects: 528
Study 37712113 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly or more stimulant use
Number of subjects: 528
Study 37712113 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 528
Study 37712421 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal serum placental growth factor (PlGF) concentration and UmA Doppler category
Number of subjects: 142
Study 37712421 — intervention group
Group type: EXPERIMENTAL
Intervention: EFW z score (Hadlock 3 formula/Marsal chart), gestational age, and UmA Doppler category
Number of subjects: 142
Study 37712510 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress hyperglycemia ratio (SHR)
Number of subjects: 2145
Study 37712510 — intervention group
Group type: EXPERIMENTAL
Intervention: High SHR (≥1.119) and NOAF
Number of subjects: 2145
Study 37712510 — intervention group
Group type: EXPERIMENTAL
Intervention: High SHR (≥1.119) and NOAF in diabetic patients
Number of subjects: 2145
Study 37712510 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR
Number of subjects: 2145
Study 37712510 — intervention group
Group type: EXPERIMENTAL
Intervention: MACE
Number of subjects: 2145
Study 37712585 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B birth dose along with routine immunisation vaccines
Number of subjects: 296
Study 37712585 — intervention group
Group type: COMPARATOR
Intervention: National vaccination schedule (control group)
Number of subjects: 296
Study 37712725 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean arterial pressure of 85 - 90 mmHg in the initial 24 hours postoperatively
Number of subjects: 174
Study 37712725 — intervention group
Group type: COMPARATOR
Intervention: Mean arterial pressure of 65 - 70 mmHg in the initial 24 hours postoperatively
Number of subjects: 174
Study 37712728 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal expiratory pressure during induced cough (measured with slow instillation of 2mL of a 0.9% saline solution)
Number of subjects: 80
Study 37712728 — intervention group
Group type: COMPARATOR
Intervention: Maximal expiratory pressure (assessed with a unidirectional valve for 40 seconds with verbal encouragement)
Number of subjects: 80
Study 37712729 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-directed weaning
Number of subjects: 94
Study 37712729 — intervention group
Group type: COMPARATOR
Intervention: Conventional weaning
Number of subjects: 94
Study 37712806 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical insufflation-exsufflation combined with chest physiotherapy
Number of subjects: 122
Study 37712806 — intervention group
Group type: COMPARATOR
Intervention: Conventional chest physiotherapy
Number of subjects: 122
Study 37712908 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab treatment for >35 days
Number of subjects: 4118
Study 37712908 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab treatment
Number of subjects: 4118
Study 37712908 — intervention group
Group type: COMPARATOR
Intervention: Untreated cohort
Number of subjects: 4118
Study 37712964 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis) for 2 weeks
Number of subjects: 30
Study 37712964 — intervention group
Group type: COMPARATOR
Intervention: Control group (no probiotic supplementation)
Number of subjects: 30
Study 37712984 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiresorptive therapy (ART)
Number of subjects: 100
Study 37712984 — intervention group
Group type: COMPARATOR
Intervention: Supportive periodontal care (SPC) without ART
Number of subjects: 100
Study 37713020 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix (120 mg orally once daily after single 360 mg loading dose)
Number of subjects: 930
Study 37713020 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide (injections every 3 months)
Number of subjects: 930
Study 37713020 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix with losartan (n=103)
Number of subjects: 930
Study 37713020 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix with amlodipine (n=229)
Number of subjects: 930
Study 37713020 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix with metoprolol (n=88)
Number of subjects: 930
Study 37713020 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix with acetylsalicylic acid (n=259)
Number of subjects: 930
Study 37713020 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix with clopidogrel (n=43)
Number of subjects: 930
Study 37713020 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix with simvastatin (n=78)
Number of subjects: 930
Study 37713020 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix with concomitant CV agents
Number of subjects: 930
Study 37713021 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 52
Study 37713021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 37713048 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyper-inflammatory profiles
Number of subjects: 193
Study 37713048 — intervention group
Group type: COMPARATOR
Intervention: Hypo-inflammatory profiles
Number of subjects: 193
Study 37713090 — intervention group
Group type: EXPERIMENTAL
Intervention: Teclistamab (1.5 mg/kg SC weekly, preceded by step-up doses of 0.06 and 0.3 mg/kg)
Number of subjects: 338
Study 37713090 — intervention group
Group type: EXPERIMENTAL
Intervention: Teclistamab
Number of subjects: 338
Study 37713103 — intervention group
Group type: EXPERIMENTAL
Intervention: Live multistrain probiotics
Number of subjects: 68
Study 37713133 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab 100 mg
Number of subjects: 335
Study 37713194 — intervention group
Group type: EXPERIMENTAL
Intervention: Household exposure to children under 6 years
Number of subjects: 682952
Study 37713194 — intervention group
Group type: EXPERIMENTAL
Intervention: Household exposure to children in daycare facilities
Number of subjects: 682952
Study 37713194 — intervention group
Group type: EXPERIMENTAL
Intervention: Household exposure to preschool children
Number of subjects: 682952
Study 37713194 — intervention group
Group type: EXPERIMENTAL
Intervention: Household exposure to primary school children (aged 6-14 years)
Number of subjects: 682952
Study 37713194 — intervention group
Group type: EXPERIMENTAL
Intervention: Household exposure to middle school children (aged 6-14 years)
Number of subjects: 682952
Study 37713194 — intervention group
Group type: EXPERIMENTAL
Intervention: Household exposure to older children (aged 15-17 years)
Number of subjects: 682952
Study 37713244 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEPTECH telehealth intervention (web-based program)
Number of subjects: 229
Study 37713244 — intervention group
Group type: COMPARATOR
Intervention: Control group (dynamic web page with publicly available informational resources about PrEP)
Number of subjects: 229
Study 37713244 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEPTECH intervention
Number of subjects: 229
Study 37713289 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent educational intervention including clinic-wide PrEP trainings, electronic health record prompt for PrEP counseling, educational videos in the waiting room.
Number of subjects: 1720
Study 37713322 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine vacuum-induced hemorrhage control device
Number of subjects: 800
Study 37713401 — intervention group
Group type: EXPERIMENTAL
Intervention: Replication-competent oncolytic adenovirus (Ad5-yCD/mutTKSR39rep-hIL-12)
Number of subjects: 15
Study 37713527 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g intravenous cefoxitin
Number of subjects: 378
Study 37713527 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 378
Study 37713598 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtenon Wharton's jelly-derived mesenchymal stem cells (WJ-MSC)
Number of subjects: 80
Study 37713598 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnovision
Number of subjects: 80
Study 37713598 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of WJ-MSC and Magnovision
Number of subjects: 80
Study 37713598 — intervention group
Group type: COMPARATOR
Intervention: Natural course (control group)
Number of subjects: 80
Study 37713657 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus chemotherapy
Number of subjects: 1581
Study 37713657 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 1581
Study 37713684 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor and clopidogrel on top of aspirin (ADAPT)
Number of subjects: 18624
Study 37713684 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor
Number of subjects: 18624
Study 37713684 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 18624
Study 37714048 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby-led weaning (BLW)
Number of subjects: 52
Study 37714048 — intervention group
Group type: COMPARATOR
Intervention: Traditional complementary feeding (TCF)
Number of subjects: 52
Study 37714168 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib plus abiraterone
Number of subjects: 796
Study 37714168 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus abiraterone
Number of subjects: 796
Study 37714386 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese version of the Columbia-Suicide Severity Rating Scale (C-SSRS)
Number of subjects: 456
Study 37714386 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 456
Study 37714670 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-Thin Descemet Stripping Automated Endothelial Keratoplasty (UT-DSAEK)
Number of subjects: 220
Study 37714670 — intervention group
Group type: COMPARATOR
Intervention: Descemet Membrane Endothelial Keratoplasty (DMEK)
Number of subjects: 220
Study 37714670 — intervention group
Group type: EXPERIMENTAL
Intervention: UT-DSAEK
Number of subjects: 220
Study 37714670 — intervention group
Group type: COMPARATOR
Intervention: DMEK
Number of subjects: 220
Study 37714726 — intervention group
Group type: EXPERIMENTAL
Intervention: Shockwave intravascular lithotripsy (IVL)
Number of subjects: 170
Study 37714726 — intervention group
Group type: COMPARATOR
Intervention: Rotational atherectomy (RA)
Number of subjects: 170
Study 37714979 — intervention group
Group type: EXPERIMENTAL
Intervention: Melanin-targeted PET imaging
Number of subjects: 3
Study 37715029 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 therapy with thyroid dysfunction
Number of subjects: 73
Study 37715029 — intervention group
Group type: COMPARATOR
Intervention: No thyroid dysfunction
Number of subjects: 73
Study 37715029 — intervention group
Group type: EXPERIMENTAL
Intervention: Male patients
Number of subjects: 73
Study 37715029 — intervention group
Group type: COMPARATOR
Intervention: Female patients
Number of subjects: 73
Study 37715029 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-PD-1-induced thyroid dysfunction
Number of subjects: 73
Study 37715123 — intervention group
Group type: EXPERIMENTAL
Intervention: SOFIA coordinated care program (extended structured consultations, group-based training of GPs and staff, handbook for signposting)
Number of subjects: 87
Study 37715123 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 87
Study 37715147 — intervention group
Group type: EXPERIMENTAL
Intervention: Video intervention providing information on domestic violence and safety improving actions.
Number of subjects: 0
Study 37715147 — intervention group
Group type: COMPARATOR
Intervention: Control group watching a video on maintaining a healthy pregnancy.
Number of subjects: 0
Study 37715152 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcurrent device applied for 60 min, 3 times per week for 4 weeks.
Number of subjects: 23
Study 37715156 — intervention group
Group type: EXPERIMENTAL
Intervention: GILL eHealth intervention
Number of subjects: 258
Study 37715156 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 258
Study 37715173 — intervention group
Group type: EXPERIMENTAL
Intervention: PENG block
Number of subjects: 84
Study 37715173 — intervention group
Group type: COMPARATOR
Intervention: Intravenous opioid
Number of subjects: 84
Study 37715201 — intervention group
Group type: EXPERIMENTAL
Intervention: DIMS spectacle lenses
Number of subjects: 158
Study 37715201 — intervention group
Group type: COMPARATOR
Intervention: SV spectacle lenses
Number of subjects: 158
Study 37715203 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention 'mindfulHeart'
Number of subjects: 128
Study 37715203 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 128
Study 37715222 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-containing beetroot juice
Number of subjects: 98
Study 37715222 — intervention group
Group type: COMPARATOR
Intervention: Nitrate-deplete beetroot juice (placebo)
Number of subjects: 98
Study 37715249 — intervention group
Group type: EXPERIMENTAL
Intervention: BCN-led group cognitive behavioural therapy (CBT)
Number of subjects: 23
Study 37715270 — intervention group
Group type: EXPERIMENTAL
Intervention: Quizartinib combined with high-dose Ara-C plus mitoxantrone (HAM)
Number of subjects: 0
Study 37715270 — intervention group
Group type: COMPARATOR
Intervention: Intensive salvage therapy
Number of subjects: 0
Study 37715270 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study 37715283 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal bracing during lifting tasks
Number of subjects: 31
Study 37715283 — intervention group
Group type: COMPARATOR
Intervention: Natural loaded breathing (without abdominal bracing)
Number of subjects: 31
Study 37715294 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 404
Study 37715294 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 404
Study 37715369 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD-10 code F11.10 (opioid abuse, uncomplicated)
Number of subjects: 307
Study 37715369 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD-10 code F11.21 (opioid dependence, in remission)
Number of subjects: 307
Study 37715369 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD-10 code F11.99 (opioid use, unspecified with unspecified opioid-induced disorder)
Number of subjects: 307
Study 37715369 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD-10 codes F11.20, F11.23, and F11.90
Number of subjects: 307
Study 37715369 — intervention group
Group type: COMPARATOR
Intervention: General findings regarding ICD code application
Number of subjects: 307
Study 37715710 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimizing sleep quality
Number of subjects: 0
Study 37715710 — intervention group
Group type: EXPERIMENTAL
Intervention: Improving mood
Number of subjects: 0
Study 37715710 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing hot flash quantity/interference
Number of subjects: 0
Study 37715730 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoximod-based combination therapy with oral temozolomide (200 mg/m2/day x 5 days in 28-day cycles)
Number of subjects: 81
Study 37715730 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoximod-based combination therapy with palliative conformal radiation
Number of subjects: 81
Study 37715730 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoximod-based combination therapy
Number of subjects: 81
Study 37715742 — intervention group
Group type: EXPERIMENTAL
Intervention: HOT-CRT (His-Purkinje conduction system pacing)
Number of subjects: 100
Study 37715742 — intervention group
Group type: COMPARATOR
Intervention: BVP (Biventricular pacing)
Number of subjects: 100
Study 37715742 — intervention group
Group type: EXPERIMENTAL
Intervention: HOT-CRT
Number of subjects: 100
Study 37715742 — intervention group
Group type: COMPARATOR
Intervention: BVP
Number of subjects: 100
Study 37715767 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth Development Accounts (YDA) treatment, n=471 girls
Number of subjects: 1260
Study 37715767 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated intervention combining YDA with multiple family group component, n=381 girls
Number of subjects: 1260
Study 37715767 — intervention group
Group type: COMPARATOR
Intervention: Control group, n=408 girls
Number of subjects: 1260
Study 37715769 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 3656
Study 37715769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3656
Study 37715773 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk plaque (HRP) on CTA
Number of subjects: 448
Study 37715773 — intervention group
Group type: COMPARATOR
Intervention: No high-risk plaque (HRP) on CTA
Number of subjects: 448
Study 37715820 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycaemic intervention (high burden)
Number of subjects: 0
Study 37715820 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure intervention (medium burden)
Number of subjects: 0
Study 37715820 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglyceride-lowering intervention (low burden)
Number of subjects: 0
Study 37715820 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycaemia requiring medical assistance
Number of subjects: 0
Study 37715858 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Plethysmography (VPPG)
Number of subjects: 216
Study 37715858 — intervention group
Group type: COMPARATOR
Intervention: Standard medical device (Welch Allyn)
Number of subjects: 216
Study 37715860 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan treated monthly (PM)
Number of subjects: 144
Study 37715860 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan treated every other month (PEOM)
Number of subjects: 144
Study 37715860 — intervention group
Group type: COMPARATOR
Intervention: Sham-treated
Number of subjects: 144
Study 37715860 — intervention group
Group type: COMPARATOR
Intervention: Untreated fellow eyes
Number of subjects: 144
Study 37715890 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening algorithm for PAD
Number of subjects: 104
Study 37715890 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized screening algorithm
Number of subjects: 104
Study 37715936 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower caregiver preparedness
Number of subjects: 424
Study 37715999 — intervention group
Group type: EXPERIMENTAL
Intervention: NexoBrid
Number of subjects: 75
Study 37715999 — intervention group
Group type: COMPARATOR
Intervention: SOC
Number of subjects: 75
Study 37716204 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-IN plus treatment as usual (TAU)
Number of subjects: 46
Study 37716204 — intervention group
Group type: COMPARATOR
Intervention: TAM plus treatment as usual (TAU)
Number of subjects: 46
Study 37716204 — intervention group
Group type: COMPARATOR
Intervention: Both ACT-IN and TAM
Number of subjects: 46
Study 37716360 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 4047
Study 37716360 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 4047
Study 37716360 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (women)
Number of subjects: 4047
Study 37716360 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (men)
Number of subjects: 4047
Study 37716365 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent SARS-CoV-2 recombinant protein vaccine (5 μg of ancestral [D614] and 5 μg of beta [B.1.351] variant spike protein, with AS03 adjuvant), administered as two 0.5 mL intramuscular injections, 21 days apart.
Number of subjects: 13002
Study 37716365 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% normal saline), administered as two 0.5 mL intramuscular injections, 21 days apart.
Number of subjects: 13002
Study 37716443 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-folic acid (IFA) supplementation
Number of subjects: 3123
Study 37716443 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplements (MMS)
Number of subjects: 3123
Study 37716443 — intervention group
Group type: COMPARATOR
Intervention: Standard nutrition education (Control)
Number of subjects: 3123
Study 37716448 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT plus rivaroxaban 2.5mg twice daily for 4 weeks
Number of subjects: 560
Study 37716448 — intervention group
Group type: COMPARATOR
Intervention: DAPT alone
Number of subjects: 560
Study 37716474 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-tracer gas single-breath washout (DTG-SBW) measurement
Number of subjects: 1782
Study 37716474 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, body composition, and wheeze
Number of subjects: 1782
Study 37716519 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined endurance and resistance eccentric training (ECC) for 4 weeks
Number of subjects: 30
Study 37716519 — intervention group
Group type: COMPARATOR
Intervention: Conventional training (CON) for 4 weeks
Number of subjects: 30
Study 37716893 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Cognitive-Behavioural Therapy (CBT) intervention, six sessions
Number of subjects: 21
Study 37716893 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (control condition)
Number of subjects: 21
Study 37716952 — intervention group
Group type: COMPARATOR
Intervention: atrasentan 0.75 mg/day
Number of subjects: 2037
Study 37716952 — intervention group
Group type: COMPARATOR
Intervention: atrasentan 1.25 mg/day
Number of subjects: 2037
Study 37716952 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMA-IR increase
Number of subjects: 2037
Study 37716967 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilientchild.dk web-based intervention
Number of subjects: 0
Study 37716990 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine use of rapid diagnostic testing at admission
Number of subjects: 12000